Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bicalutamide
Drug ID BADD_D00271
Description Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Indications and Usage For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.
Marketing Status Prescription; Discontinued
ATC Code L02BB03
DrugBank ID DB01128
KEGG ID D00961
MeSH ID C053541
PubChem ID 2375
TTD Drug ID D0V9BD
NDC Product Code 60429-177; 70518-2993; 51846-1028; 16714-816; 62559-680; 0904-6019; 16729-023; 43265-0705; 15308-0360; 54893-0001; 49711-1504; 65841-613; 43265-7195; 49711-1509; 71205-577; 68382-224; 47335-485; 63629-8308; 63759-0004; 62559-890; 53104-7664; 46014-1111; 58623-0068
Synonyms bicalutamide | 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide | Casodex | Cosudex | ICI-176334 | ICI 176334
Chemical Information
Molecular Formula C18H14F4N2O4S
CAS Registry Number 90357-06-5
SMILES CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pollakiuria20.02.02.0070.006444%
Polyuria20.02.03.0020.009667%Not Available
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.0070.006444%
Proctalgia07.03.02.0010.019333%
Proctitis07.08.04.0010.009667%
Productive cough22.02.03.0050.006444%
Prostate cancer metastatic21.04.02.004; 16.25.01.0020.010087%Not Available
Prostatic disorder21.04.01.001--Not Available
Prostatic specific antigen increased13.22.01.0010.125667%Not Available
Prothrombin time prolonged13.01.02.0120.006444%Not Available
Pruritus23.03.12.001--
Pulmonary embolism24.01.06.001; 22.06.02.0010.048333%Not Available
Pulmonary fibrosis22.01.02.0060.007565%
Pulmonary hypertension24.08.03.002; 22.06.01.0010.002522%
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.0030.090222%
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.0030.006444%Not Available
Rash generalised23.03.13.002--Not Available
Rash pruritic23.03.12.0020.012889%Not Available
Rectal haemorrhage07.12.03.001; 24.07.02.0180.022556%
Rectal ulcer07.04.01.0020.006444%
Red blood cell count decreased13.01.05.0070.006444%Not Available
Renal failure20.01.03.0050.008406%Not Available
Respiratory disorder22.02.07.0020.006444%Not Available
Respiratory distress22.02.01.0120.006444%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.010087%
Retinal vein occlusion24.01.07.006; 06.10.01.0100.006444%Not Available
Rhabdomyolysis15.05.05.0020.035445%
Rhinitis22.07.03.006; 11.01.13.004--
The 11th Page    First    Pre   11 12 13 14 15    Next   Last    Total 17 Pages